ProstACT Global Phase 3 Update: First Patient Dosed, Part 1 Preliminary Data Plans ConfirmedTelix recently announced that its lead prostate cancer candidate TLX591 (lutetium-177 ro...
This page summarizes the latest approvals issued by the U.S. Food and Drug Administration (FDA). The list includes newly approved therapies as well as additional indications for ex...